Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20047141 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CYP2D6CHRNA7KDM4EMEN1 | |
| SCHEMBL24733365 | 0.76 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL992596 | 0.75 | GAA (0.44) | ALDH1A1 | |
| SCHEMBL13328908 | 0.74 | CYP2D6 (0.43) | ALDH1A1CYP2D6CHRNA7KDM4EMEN1 | |
| SCHEMBL24713300 | 0.74 | CYP2D6 (0.38) | ALDH1A1CYP2D6CHRNA7KDM4EMEN1 | |
| SCHEMBL24422420 | 0.72 | NPSR1 (0.37) | CYP2D6 | |
| SCHEMBL10098670 | 0.72 | CYP2D6 (0.42) | ALDH1A1CYP2D6CHRNA7KDM4EMEN1 | |
| SCHEMBL25443833 | 0.71 | NPSR1 (0.36) | CYP2D6 | |
| SCHEMBL23153462 | 0.71 | ALDH1A1 (0.37) | ALDH1A1CYP2D6KDM4EMEN1LMNA | |
| SCHEMBL7853065 | 0.70 | CYP2D6 (0.41) | ALDH1A1CYP2D6CHRNA7KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122050-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-113122050-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113122050-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-103172589-A | Thiazolyl-dihydroquinazolines | BOEHRINGER INGELHEIM INT | 2013-06-26 | — | — | CN | disclosed |
| EP-2018385-B1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INT (DE) | 2013-05-15 | — | — | EP | disclosed |
| CN-101460505-B | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INT | 2013-03-20 | — | — | CN | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| CN-101460505-A | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INT (DE) | 2009-06-17 | — | — | CN | disclosed |
| EP-2018385-A1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007115929-A1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | QDPR, NQO2, DHPS | ALDH1A1 815/4885CYP2D6 17/4885CHRNA7 2325/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | ALDH1A1 726/4885CYP2D6 7/4885CHRNA7 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.